Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IFRX - InflaRx N.V.

IEX Last Trade
2.55
-0.020   -0.784%

Share volume: 2,008
Last Updated: Thu 26 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$2.57
-0.02
-0.78%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.40%
1 Month
14.09%
3 Months
62.99%
6 Months
56.88%
1 Year
48.52%
2 Year
-22.77%
Key data
Stock price
$2.55
P/E Ratio 
0.00
DAY RANGE
$2.49 - $2.58
EPS 
$0.00
52 WEEK RANGE
$1.24 - $2.82
52 WEEK CHANGE
$51.20
MARKET CAP 
93.624 M
YIELD 
N/A
SHARES OUTSTANDING 
58.883 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
BETA 
0.39
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$226,663
AVERAGE 30 VOLUME 
$375,668
Company detail
CEO: Niels C. Riedemann
Region: US
Website: inflarx.de
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

InflaRx N.V. discovers and develops inhibitors using C5a technology. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases.

Recent news